

CORRIGENDUM

Corrigendum to ‘Editor’s Choice — European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Vascular Graft and Endograft Infections’ [European Journal of Vascular & Endovascular Surgery 59/3 (2020) 339–384]

Nabil Chakfé ^{a,e}, Holger Diener ^a, Anne Lejay ^{a,e}, Ojan Assadian ^a, Xavier Berard ^a, Jocelyne Caillon ^{a,e}, Inge Fourneau ^a, Andor W.J.M. Glaudemans ^{a,d}, Igor Koncar ^a, Jes Lindholt ^a, Germano Melissano ^a, Ben R. Saleem ^a, Eric Senneville ^{a,e}, Riemer H.J.A. Slart ^{a,d}, Zoltan Szeberin ^a, Maarit Venermo ^a, Frank Vermassen ^a, Thomas R. Wyss ^a

ESVS Guidelines Committee ^b, Gert J. de Borst, Frederico B. Gonçalves, Stavros K. Kakkos, Philippe Kolh, Riikka Tulamo, Melina V. de Ceniga

Document Reviewers ^c, Regula S. von Allmen, Jos C. van den Berg, E. Sebastian Debus, Mark J.W. Koelemay, Jose P. Linares-Palomino, Gregory L. Moneta, Jean-Baptiste Ricco, Anders Wanhainen

The authors regret there were mistakes in Table 12 concerning adjusted risk estimation for surgical site infections of the lower limbs. The authors would like to thank Dr Tresson and colleagues for their careful reading and to apologise for any inconvenience. Table 12 should be read as below:

Risk factor	Adjusted risk estimation OR (95% CI)	Reference
Female sex	1.44 (1.28–1.63)	Greenblatt <i>et al.</i> (2011) ²⁷⁸
Obesity	2.08 (1.78–2.43)	Greenblatt <i>et al.</i> (2011) ²⁷⁸
Body mass index ≥ 25	1.78 (1.23–2.57)	Davis <i>et al.</i> (2017) ²⁷⁹
	1.28 (1.10–1.49)	Greenblatt <i>et al.</i> (2011) ²⁷⁸
Hypertension	4.29 (2.74–6.72)	Davis <i>et al.</i> (2017) ²⁷⁹
Chronic obstructive pulmonary disease	2.10 (1.07–4.09)	Leekha <i>et al.</i> (2016) ²⁸⁰
	1.23 (1.03–1.43)	Greenblatt <i>et al.</i> (2011) ²⁷⁸
History of chronic heart failure	1.86 (1.13–3.05)	Davis <i>et al.</i> (2017) ²⁷⁹
Creatinine > 1.5 mg/dL	1.57 (1.09–2.27)	Davis <i>et al.</i> (2017) ²⁷⁹
Dialysis	1.51 (1.08–2.11)	Greenblatt <i>et al.</i> (2011) ²⁷⁸
	4.35 (3.45–5.47)	Davis <i>et al.</i> (2017) ²⁷⁹
Critical limb ischaemia	2.91 (1.61–5.27)	Leekha <i>et al.</i> (2016) ²⁸⁰
Re-intervention	11.00 (1.90–63.00)	Brothers <i>et al.</i> (2009) ²¹¹
Peak glucose > 180 mg/dL	1.99 (1.53–2.57)	Davis <i>et al.</i> (2017) ²⁷⁹
Hyponatremia < 134 g/dL	1.20 (1.02–1.42)	Greenblatt <i>et al.</i> (2011) ²⁷⁸
Major amputation	12.00 (4.10–34.00)	Brothers <i>et al.</i> (2009) ²¹¹
Prior revascularisation	2.68 (1.38–5.22)	Leekha <i>et al.</i> (2016) ²⁸⁰
	1.57 (1.04–2.38)	Davis <i>et al.</i> (2017) ²⁷⁹
Any platelet medication	4.29 (3.41–5.41)	Davis <i>et al.</i> (2017) ²⁷⁹

For full list of Author's affiliations, please refer to Appendix available with the original article

☆ The ESVS 2020 Guidelines on Management of Vascular Graft Infections are Endorsed by the European Association of Nuclear Medicine (EANM).

DOI of original article: <https://doi.org/10.1016/j.ejvs.2019.10.016>.

^a **Writing Committee:** Nabil Chakfé (Chair)* (Strasbourg, France), Holger Diener (Co-Chair) (Hamburg, Germany), Anne Lejay (Strasbourg, France), Ojan Assadian (Vienna, Austria), Xavier Berard (Bordeaux, France), Jocelyne Caillon (Nantes, France), Inge Fourneau (Leuven, Belgium), Andor W.J.M. Glaudemans (Groningen, The Netherlands), Igor Koncar (Belgrade, Serbia), Jes Lindholt (Odense, Denmark), Germano Melissano (Milan, Italy), Ben R. Saleem (Groningen, The Netherlands), Eric Senneville (Tourcoing, France), Riemer H.J.A. Slart (Groningen, The Netherlands), Zoltan Szeberin (Budapest, Hungary), Omke Teebken (Peine, Germany), Maarit Venermo (Helsinki, Finland), Frank Vermassen (Ghent, Belgium), Thomas R. Wyss (Bern, Switzerland).

^b **ESVS Guidelines Committee:** Gert J. de Borst (Chair) (Utrecht, The Netherlands), Frederico Bastos Gonçalves (Lisbon, Portugal), Stavros K. Kakkos (Patras, Greece), Philippe Kolh (Liège, Belgium), Riikka Tulamo (Helsinki, Finland), Melina Vega de Ceniga (Review coordinator) (Bizkaia, Spain).

^c **Document Reviewers:** Regula S. von Allmen (Gallen, Switzerland), Jos C. van den Berg (Bern, Switzerland), E. Sebastian Debus (Hamburg-Eppendorf, Germany), Mark J.W. Koelemay (Amsterdam, The Netherlands), Jose P. Linares-Palomino (Granada, Spain), Gregory L.L. Moneta (Portland, OR, USA), Jean-Baptiste Ricco (Poitiers, France), Anders Wanhainen (Uppsala, Sweden).

^d **European Association of Nuclear Medicine.**

^e **Groupe de Recherche sur les Infections de Prothèses.**

* Corresponding author. E-mail address: nabil.chakfe@chru-strasbourg.fr (Nabil Chakfé)

1078-5884/© 2020 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

<https://doi.org/10.1016/j.ejvs.2020.07.080>